| Document Date: 2008-06-04 11:44:27
Open Document File Size: 38,40 KBShare Result on Facebook
City Brussels / / Company Schwarz Pharma / Euronext Brussels / UCB S.A. / UCB Group / / Continent Europe / / Country Belgium / United States / / Currency EUR / / / Event Product Recall / FDA Phase / Product Release / Earnings Announcement / Product Issues / Company Listing Change / / IndustryTerm biotechnology products / treatment of the signs and symptoms / pharmaceutical / biopharmaceutical industry / manufacturing process / / MedicalCondition disease / idiopathic Parkinson’s disease / Hallucinations / nausea / Parkinson's Disease / RLS / orthostatic hypotension / advanced-stage Parkinson's disease / allergy/respiratory diseases / idiopathic Parkinson's disease / neuroleptic malignant syndrome / dizziness / severe disease / central nervous system disorders / immune and inflammatory disorders / syndrome / / MedicalTreatment adjunctive therapy / / Organization UCB-Group / European Commission / Committee for Medicinal Products for Human Use / European Medicines Evaluation Agency / / Person Iris Loew-Friedrich / Antje Witte / / / Position Chief Medical Officer / Vice-President Corporate Communications & Investor Relations / / Product Neupro / dopamine agonists / Forward-Looking Statement This / Neupro® patches / / Technology biotechnology / / URL www.ucb-group.com / /
SocialTag |
Press Release - Regulated information UCB to implement full cold-chain for Neupro®